Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 390057
                    [Title] => Halted trials: Celecoxib tied to rise in CV risk
                    [Summary] => Celecoxib cannot be recommended to reduce colorectal cancer risk — despite its proven efficacy for that indication — until more is known about its potential cardiovascular risks, coordinators of two chemoprevention trials concluded.
                    [DatePublished] => 2007-03-18 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

ADENOMATOUS POLYP PREVENTION

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 390057
                    [Title] => Halted trials: Celecoxib tied to rise in CV risk
                    [Summary] => Celecoxib cannot be recommended to reduce colorectal cancer risk — despite its proven efficacy for that indication — until more is known about its potential cardiovascular risks, coordinators of two chemoprevention trials concluded.
                    [DatePublished] => 2007-03-18 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Halted trials: Celecoxib tied to rise in CV risk

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | March 18, 2007 - 12:00am

Celecoxib cannot be recommended to reduce colorectal cancer risk — despite its proven efficacy for that indication —...

Opinion